Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Oncolytics initiates patient enrollment in phase II trial of Reolysin in NSCLC

March 16, 2009

T-115 shows potent antitumor activity in vitro and in vivo

March 16, 2009

FDA approves Molecular Insight's SPA for phase II registration trial of Azedra

March 13, 2009

Sutent increases progression-free survival in advanced pancreatic islet cell tumors

March 13, 2009

Novel proteasome inhibitors claimed by Millennium Pharmaceuticals

March 13, 2009

StemEx receives orphan medicinal product designation in Europe

March 12, 2009

Merrion commences dosing of Orazol in U.S. clinical study

March 12, 2009

Custirsen combined with docetaxel shows increased efficacy and safety in prostate cancer

March 12, 2009

Celator enrolls first patient in phase II CPX-351 trial in acute myeloid leukemia

March 12, 2009

Paladin files new drug submission for Trelstar 6-month formulation

March 12, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...